Graybill Wealth Management LTD. Invests $2.59 Million in Waters Corporation $WAT

Graybill Wealth Management LTD. bought a new stake in Waters Corporation (NYSE:WAT) during the 3rd quarter, HoldingsChannel reports. The fund bought 8,641 shares of the medical instruments supplier’s stock, valued at approximately $2,591,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mondrian Investment Partners LTD acquired a new stake in shares of Waters in the 3rd quarter valued at approximately $1,397,000. Alberta Investment Management Corp acquired a new position in Waters during the third quarter worth $4,677,000. Vanguard Group Inc. grew its holdings in Waters by 3.3% during the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock worth $2,295,612,000 after acquiring an additional 246,128 shares during the period. Mackenzie Financial Corp raised its position in Waters by 12.2% in the third quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock worth $69,512,000 after acquiring an additional 25,182 shares in the last quarter. Finally, Veritas Asset Management LLP purchased a new position in Waters in the third quarter worth $175,320,000. 94.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on WAT. HSBC started coverage on shares of Waters in a research report on Tuesday, January 27th. They set a “buy” rating and a $460.00 target price on the stock. Barclays initiated coverage on shares of Waters in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $400.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Waters in a report on Wednesday, January 21st. Guggenheim restated a “buy” rating and set a $440.00 target price on shares of Waters in a research report on Tuesday, February 10th. Finally, Bank of America dropped their target price on shares of Waters from $410.00 to $350.00 and set a “neutral” rating for the company in a report on Tuesday, February 10th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $393.84.

Waters Stock Up 2.4%

Waters stock opened at $297.09 on Wednesday. Waters Corporation has a fifty-two week low of $275.05 and a fifty-two week high of $414.15. The firm has a market capitalization of $29.14 billion, a price-to-earnings ratio of 27.59, a price-to-earnings-growth ratio of 2.00 and a beta of 1.20. The stock’s fifty day moving average is $348.50 and its two-hundred day moving average is $351.50. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.27 and a current ratio of 1.73.

Waters (NYSE:WAT) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $4.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.50 by $0.03. Waters had a return on equity of 34.79% and a net margin of 20.30%.The business had revenue of $932.36 million during the quarter, compared to the consensus estimate of $928.17 million. During the same quarter in the previous year, the company posted $4.10 EPS. The business’s revenue was up 6.9% on a year-over-year basis. Waters has set its FY 2026 guidance at 14.300-14.500 EPS and its Q1 2026 guidance at 2.250-2.350 EPS. Analysts predict that Waters Corporation will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.